

Filed On Behalf Of:

Novartis AG and LTS Lohmann Therapie-Systeme AG

By:

Raymond R. Mandra
ExelonPatchIPR@fchs.com
(212) 218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

NOVEN PHARMACEUTICALS INC.,
Petitioner

v.

NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,
Patent Owners

Inter Partes Review No. 2014-00550

U.S. Patent 6,335,031

PATENT OWNERS' UPDATED MANDATORY NOTICES
UNDER 37 C.F.R. § 42.8(a)(3)

Pursuant to 37 C.F.R. § 42.8(a)(3), the following updated mandatory notices are being filed with the Patent Trial and Appeal Board (“Board”).

REAL PARTY-IN-INTEREST

The real party-in-interest information has not changed.

RELATED MATTERS

The Patent Owners hereby notify the Board of changes in the matters related to the present proceedings pursuant to 37 C.F.R. § 42.8(b)(2).

U.S. Patent 6,335,031 is being asserted in the following patent infringement lawsuits: (1) Novartis Pharm. Corp. et al. v. Par Pharm. Inc. et al., 1:11-cv-01077 (D. Del.); (2) Novartis Pharm. Corp. et al. v. Watson Labs. Inc. et al., 1:11-cv-01112 (D. Del.); (3) Novartis Pharm. Corp. et al. v. Actavis, Inc. et al., 1:13-cv-00371 (D. Del.); (4) Novartis Pharm. Corp. et al. v. Noven Pharm. Inc. et al., 1:13-cv-00527 (D. Del.); (5) Novartis Pharm. Corp. et al. v. Par Pharm. Inc., 1:13-cv-01467 (D. Del.); (6) Novartis Pharm. Corp. et al. v. Noven Pharm. Inc., 1:14-cv-00111 (D. Del.); (7) Novartis Pharm. Corp. et al. v. Mylan Inc. et al., 1:14-cv-00777 (D. Del.); (8) Novartis Pharm. Corp. et al. v. Mylan Inc. et al., 1:14-cv-00106 (N.D.W.V.); (9) Novartis Pharm. Corp. et al. v. Zydus Noveltech Inc. et al., 1:14-cv-01104 (D. Del.); (10) Novartis Pharm. Corp. et al. v. Zydus Noveltech Inc. et al., 1:14-cv-05405 (D.N.J.); (11) Watson Labs. Inc. et al. v. Novartis Pharm. Corp. et al., 14-1799 (C.A.F.C.); (12) Novartis Pharm. Corp. et al. v. Par Pharm.

Inc. et al., 15-1061 (C.A.F.C.); (13) Novartis Pharm. Corp. et al. v. Par Pharm. Inc., 15-1062 (C.A.F.C.); (14) Par Pharm. Inc. v. Novartis Pharm. Corp. et al., 15-1120 (C.A.F.C.); and (15) Par Pharm. Inc. v. Novartis Pharm. Corp., 15-1121 (C.A.F.C.).

LEAD AND BACK-UP COUNSEL

The lead and back-up counsel information has not changed.

SERVICE INFORMATION

The service information has not changed.

POWER OF ATTORNEY

The power of attorney information has not changed.

Respectfully submitted,

Dated: October 31, 2014

/Raymond R. Mandra /
Raymond R. Mandra
Registration No. 34,382
Lead Counsel for Patent Owners
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100

CERTIFICATE OF SERVICE

I certify that a copy of the Patent Owners' Updated Mandatory Notices Under 37 C.F.R. § 42.8(a)(3) was served on October 31, 2014 by causing it to be sent by email to counsel for Petitioner at the following email addresses:

Steven J. Lee (slee@kenyon.com)

Michael K. Levy (mlevy@kenyon.com)

Dated: October 31, 2014

/Raymond R. Mandra /
Raymond R. Mandra
Registration No. 34,382
FITZPATRICK, CELLA, HARPER
& SCINTO
1290 Avenue of the Americas
New York, NY 10104-3800
Tel. 212-218-2100